期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
Role of long non-coding RNAs in non-alcoholic fatty liver disease
1
作者 Anju Mullath Murali Krishna 《World Journal of Meta-Analysis》 2024年第3期1-5,共5页
Non-alcoholic fatty liver disease(NAFLD)is emerging as a common cause of chronic liver disease in children and adults.NAFLD can progress to steatohepa-titis and potentially even hepatocellular carcinoma.Early identifi... Non-alcoholic fatty liver disease(NAFLD)is emerging as a common cause of chronic liver disease in children and adults.NAFLD can progress to steatohepa-titis and potentially even hepatocellular carcinoma.Early identification of pati-ents at risk for progressive disease is crucial for managing NAFLD.Recent studies have identified long noncoding RNAs(lncRNAs),circular RNAs,and microRNAs as playing important roles in the pathogenesis of NAFLD.These noncoding RNAs are involved in modulating several metabolic pathways such as hepatic glucose and lipid metabolism,oxidative stress,and even carcinogenesis.Elevated levels of lncARSR and lncRNA nuclear-enriched abundant transcript 1 have been found in patients with NAFLD.In addition,lncRNAs such as PRYP4-3 and RP11-128N14.5 can distinguish patients with NAFLD from healthy indi-viduals.Increased MEG3 expression has been observed in both NAFLD and non-alcoholic steatohepatitis,suggesting that it may help predict patients at risk for disease progression.With advances in transcriptomics,we may discover additional targets to help in the identification and prognostication of NAFLD. 展开更多
关键词 Long noncoding rna Non-alcoholic fatty liver disease Plasmacytoma variant translocation 1 Nuclear-enriched abundant transcript 1 Muscle-and adiposeassociated long intergenic non-coding rna H19
下载PDF
Danhongqing formula alleviates cholestatic liver fibrosis by downregulating long non-coding RNA H19 derived from cholangiocytes and inhibiting hepatic stellate cell activation
2
作者 Meng Li Yang Zhou +2 位作者 Hui Zhu Lie-ming Xu Jian Ping 《Journal of Integrative Medicine》 SCIE CAS CSCD 2024年第2期188-198,共11页
Objective:This study explores the mechanism of action of Danhongqing formula(DHQ),a compoundbased Chinese medicine formula,in the treatment of cholestatic liver fibrosis.Methods:In vivo experiments were conducted usin... Objective:This study explores the mechanism of action of Danhongqing formula(DHQ),a compoundbased Chinese medicine formula,in the treatment of cholestatic liver fibrosis.Methods:In vivo experiments were conducted using 8-week-old multidrug resistance protein 2 knockout(Mdr2-/-)mice as an animal model of cholestatic liver fibrosis.DHQ was administered orally for 8 weeks,and its impact on cholestatic liver fibrosis was evaluated by assessing liver function,liver histopathology,and the expression of liver fibrosis-related proteins.Real-time polymerase chain reaction,Western blot,immunohistochemistry and other methods were used to observe the effects of DHQ on long non-coding RNA H19(H19)and signal transducer and activator of transcription 3(STAT3)phosphorylation in the liver tissue of Mdr2-/-mice.In addition,cholangiocytes and hepatic stellate cells(HSCs)were cultured in vitro to measure the effects of bile acids on cholangiocyte injury and H19 expression.Cholangiocytes overexpressing H19 were constructed,and a conditioned medium containing H19 was collected to measure its effects on STAT3 protein expression and cell activation.The intervention effect of DHQ on these processes was also investigated.HSCs overexpressing H19 were constructed to measure the impact of H19 on cell activation and assess the intervention effect of DHQ.Results:DHQ alleviated liver injury,ductular reaction,and fibrosis in Mdr2-/-mice,and inhibited H19expression,STAT3 expression and STAT3 phosphorylation.This formula also reduced hydrophobic bile acid-induced cholangiocyte injury and the upregulation of H19,inhibited the activation of HSCs induced by cholangiocyte-derived conditioned medium,and decreased the expression of activation markers in HSCs.The overexpression of H19 in a human HSC line confirmed that H19 promoted STAT3 phosphorylation and HSC activation,and DHQ was able to successfully inhibit these effects.Conclusion:DHQ effectively alleviated spontaneous cholestatic liver fibrosis in Mdr2-/-mice by inhibiting H19 upregulation in cholangiocytes and preventing the inhibition of STAT3 phosphorylation in HSC,thereby suppressing cell activation. 展开更多
关键词 Liver cirrhosis BILIARY Long non-coding rna H19 Danhongqing formula CHOLANGIOCYTE Hepatic stellate cells STAT3 transcription factor
原文传递
长链非编码RNA PCAT19通过负调控p53水平促进非小细胞肺癌细胞的增殖
3
作者 刘艳红 贾金广 王富霞 《临床肺科杂志》 2020年第11期1741-1745,共5页
目的检测长链非编码RNA PCAT19在非小细胞肺癌中的表达水平及对非小细胞肺癌进展的影响。方法收集2013年1月-2015年1月在我院接受手术治疗的NSCLC患者78例,男性52例,女性26例,年龄37-72岁,记录患者的一般临床资料;qRT-PCR检测非小细胞... 目的检测长链非编码RNA PCAT19在非小细胞肺癌中的表达水平及对非小细胞肺癌进展的影响。方法收集2013年1月-2015年1月在我院接受手术治疗的NSCLC患者78例,男性52例,女性26例,年龄37-72岁,记录患者的一般临床资料;qRT-PCR检测非小细胞肺癌肿瘤组织、癌旁组织中PCAT19和p53 mRNA的相对表达水平,根据PCAT19 mRNA相对表达水平将患者分为PCAT19高表达组和低表达组;Kaplan-Meier法计算患者的生存率,log-rank比较PCAT19高表达组和低表达组患者的生存率;Pearson相关性分析NSCLC组织中PCAT19的表达水平与p53 mRNA的相关性;Western blot实验检测PCAT19和p53蛋白表达水平;细胞增殖实验检测各组细胞的增殖能力。结果 PCAT19在非小细胞肺癌组织中的平均表达水平显著高于癌旁组织(t=19.662,P<0.001),PCAT19高表达组55例,PCAT19低表达组23例,PCAT19高表达组与PCAT19低表达组患者在性别、年龄、病理类型和分化程度之间差异无统计学意义(P>0.05),在TNM分期和淋巴结转移之间有差异(P<0.05),且PCAT19高表达组患者的5年生存率显著低于PCAT19低表达组(HR=1.866,95%CI:1.020-3.414,P=0.043);非小细胞肺癌组织中PCAT19的表达水平与p53 mRNA水平呈负相关(r=-0.279,P=0.014);PCAT19组p53 mRNA水平1.51±0.18与对照组2.7±0.16相比显著降低(q=13.221,P<0.001),PCAT19-siRNA组p53 mRNA 3.28±0.16与对照组2.70±0.16相比显著增加(q=6.831,P=0.009);PCAT19组细胞的增殖能力强于对照组和阴性对照组,PCAT19-siRNA组细胞的增殖能力弱于对照组和阴性对照组,PCAT19+p53组与PCAT19组相比细胞的增殖能力减弱。结论 PCAT19通过负调控p53肿瘤抑制途径,促进非小细胞肺癌细胞的增殖,与肿瘤的分期和淋巴结转移有关。 展开更多
关键词 非小细胞肺癌 前列腺癌相关非编码rna转录物19 抑癌基因P53 细胞增殖
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部